Fighting the Good Fight

Context

Pharmaceutical behemoth Pfizer, whose mRNA breakthrough turned the tide against COVID, was the field marshal of the pandemic response. At the peak of the crisis, the company stood tall. But when the smoke cleared, a new campaign began: a brutal, high-stakes battle for survival.

Founded in 1849 by German-American cousins Charles Pfizer and Charles Erhart, Pfizer has a long record of rallying through crises. From churning out penicillin during World War II to making modern medicine accessible around the globe, the company knows how to march in step with history.

But nothing quite matched the chaos of Pfizer’s post-pandemic struggles. 

Real-Life Story

After a record US$100.3bn in revenue in 2022, the following year saw a 42% drop, landing at $58.5bn. COVID-19 product revenue alone nosedived nearly 90%. The market wasn’t merciful. Pfizer’s stock took a hammering – down 40% – and its market capitalisation halved from $350bn in 2021 to $157bn.

It was the kind of rout that would force any leader to bunker down and rethink strategy. Albert Bourla, Pfizer’s CEO in this crisis, called it what it was: a necessary reset. The actions Pfizer was taking were “necessary for the company’s survival and future growth,” he said, as layoffs swept through the ranks and entire divisions were reassessed.

The Cost of Peacetime Unpreparedness

The firm’s troubles weren’t just about vanishing demand. They revealed an Achilles’ heel: overdependence on pandemic-era products. With government contracts drying up and the commercial market proving more volatile than expected, Pfizer was left exposed. 

The company’s sickle cell treatment investment worth $5.4bn was shelved. Its foray into obesity drugs floundered, as competitors like Eli Lilly and Novo Nordisk stormed ahead.

Even Pfizer’s famed pipeline appeared to have stalled. 2024 guidance rattled shareholders: expected COVID-19 sales were slashed to $8bn while diluted earnings per share collapsed by 93%. One internal report summed it up grimly: the company’s stock price dropped by over 40% in 2023. In military terms, this was a full-blown retreat under fire.

Strategic Counteroffensive: A Five-Pronged Campaign

Bourla and his generals wasted no time. What followed was a disciplined, five-pronged strategic counteroffensive:

1) Aggressive Cost Discipline

Pfizer launched a $4bn savings mission by 2024, with more to come – an additional $1.5bn by 2027. This meant tough calls: headcount reductions, real estate downsizing, and trimming underperforming assets. Operations were stripped down to fighting weight.

2) Commercial Market Manoeuvres

With governments stepping back, Pfizer pivoted to commercialise its COVID-19 products. The COVID treatment Paxlovid began private-market sales in late 2023, with pricing now brokered with insurers. Simultaneously, the company broadened access in low- and middle-income markets, reinforcing its global presence.

3) Pipeline Diversification and Acquisition Firepower

Recognising the perils of narrow reliance, Pfizer doubled down on R&D and acquisitions. A major $43bn acquisition of cancer firm Seagen marked a bold flanking manoeuvre into high-value oncology markets. Rare diseases and gene therapies are now mission-critical.

4) Financial Fortification

Pfizer forecasted 2025 revenues of $61bn to $64bn, aiming to rebuild its financial armoury. Adjusted EPS targets of $2.80 to $3.00 suggested a stabilising position. Margin improvements and lower debt levels provided the fuel for renewed offensive action.

5) Troop Morale and Culture

Even amid layoffs, leadership prioritised transparent communication. Bourla acknowledged the internal toll but remained resolute about Pfizer’s long-term trajectory. Re-engagement became key to restoring morale in the ranks.

Signs of Resurgence on the Battlefield

By the first quarter of 2024, Pfizer was regaining its footing. Earnings exceeded Wall Street expectations, and the stock rallied 6%. The company refocused on early-stage licensing deals, especially in promising fronts such as obesity treatment. Its non-COVID portfolio is expected to grow 6% to 8% operationally, led by oncology and rare disease pipelines.

Fast-forward to 2025, and Pfizer’s stabilisation efforts are beginning to bear fruit. The company reported $13.7bn in Q1 revenues, with adjusted EPS of $0.92, up 12% year-on-year, despite an 8% drop in revenues from falling Paxlovid sales and Medicare policy shifts.

Cost realignment is tracking ahead of schedule. Pfizer expects to surpass $4.5bn in net savings by year-end, boosted by digital integration, process simplification, and manufacturing optimisation. A further $1.5bn in cost savings is projected by 2027.

Meanwhile, the oncology portfolio is advancing, with new approvals and pipeline candidates offering fresh strategic positions.

A Stronger, Leaner Force for the Long Haul

Pfizer’s post-pandemic manoeuvre repositions it for the next global health battle. R&D remains the spearhead. From gene therapy to obesity, from rare diseases to new vaccine platforms, Pfizer’s arsenal is expanding. A leaner operating model and sharper commercial focus are the hallmarks of this new doctrine.

Bourla’s battlefield discipline has proven essential. Strategic agility and focused execution remain at the core of Pfizer’s war manual. The leadership continues to navigate market volatility, from exchange rate skirmishes to policy ambushes such as Medicare Part D redesign – with a calm, tactical hand.

PostScript: Pfizer’s willingness to cut deep, invest wisely, and double down on innovation has laid the foundation for a more balanced, resilient future. In the fog of post-pandemic war, the company’s mission is to adapt to survive and innovate to lead. The fight is far from over, but the company is no longer retreating. It’s on the march once again.

Key Lessons

1) Don’t Build on Sandbags

Revenue from one-off wins, like pandemic products, may balloon profits, but they won’t hold when the tide turns. Build sustainable income streams to weather tomorrow’s storms, not just today’s battles.

2) Five-Pillar Strategies Provide Cover Fire

Pfizer’s war plan – cost discipline, market transition, pipeline diversification, financial optimisation, and employee engagement – acted as a defensive shield while plotting its counterattack. A multi-front strategy ensures survival when no single fix will do.

3) Acquisitions Must Advance the Front Line  

For Pfizer, acquiring Seagen meant redeploying capital towards the next battleground: oncology. Strategic acquisitions aren’t about empire building but about arming for the next fight.

4) Leadership Agility Wins Terrain

Bourla’s navigation of pricing shifts, regulatory changes, and volatile demand showed adaptive command. WarTime CEOs lead like guerrilla tacticians able to switch tactics at a moment’s notice while keeping eyes on the mission.

Find Out More

Do you want to learn more about the practical tools noted above? Are you aiming to find the right support for scaling up your business?

Feel free to click the button below if you feel you might need help.

Until next week, may the force be with you.

Kevin

P.S. Enjoyed this newsletter? Forward it to a friend and have them sign up here.

Whenever You’re Ready, Here are 4 Ways We Can Help You …

1. Business Turnaround and Transformation Tools, including templates, checklists, and dashboards

2. MasterMind Sessions - to teach you how to execute business turnarounds and transformations

3. One-on-One Calls - for mentoring with our expert panel

4. Promotion - amplifying the message of your business through sponsors